A. Zomorrodi 
We appreciate the comments on our letter [1] .
As we have already mentioned in our first correspondence, there should be more data on COVID-19 among organ transplant patients. The mortality in COVID-19 is considered higher than other respiratory virus infections and the mortality rate might be varied in different settings based on demographic characteristics, quality of care, comorbidity, stage of the disease at initial presentation and outbreak density. For example, an elderly with diabetes might have increased chance of mortality regardless of having organ transplantation [2] . The effect of immunosuppressive drug is also an important issue to be discussed. For example, cyclosporine, a classical immunosuppressive agent, was previously mentioned for its effect against corona virus infection [3] . Finally, apart from renal transplantation, there are transplantations of other organs where we have still no data on COVID-19. For example, it is still an interesting issue about the mortality among COVID-19 patients with hematological stem cell transplantation [4] .
The study on kidney transplant recipients with COVID-19 might show the high mortal-
ity, however, it has to be compared with the background situation in that setting. Also, it should address for the use of immunosuppressive drugs in that setting. As we have stated in our first correspondence, the available data are not enough to make a solid conclusion. 